{"id":93,"date":"2022-11-02T09:56:17","date_gmt":"2022-11-02T09:56:17","guid":{"rendered":"https:\/\/oxb.themarketingpod.co.uk\/?page_id=93"},"modified":"2026-02-27T18:35:18","modified_gmt":"2026-02-27T18:35:18","slug":"information","status":"publish","type":"page","link":"https:\/\/oxb.com\/information\/","title":{"rendered":"Investor Information"},"content":{"rendered":"<h2 class=\"block-title\">Financial calendar<\/h2>\n<table class=\"views-table cols-2\">\n<thead>\n<tr>\n<th class=\"views-field views-field-title\" scope=\"col\">Upcoming events<\/th>\n<th class=\"views-field views-field-field-guidance\" scope=\"col\">Date<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr class=\"odd views-row-first views-row-last\">\n<td class=\"views-field views-field-title\">2022 Interim Results Announcement<\/td>\n<td class=\"views-field views-field-field-guidance\">Q3 2022<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 class=\"block-title\">Analyst coverage<\/h2>\n<p>The following analysts cover Oxford Biomedica:<\/p>\n<table class=\"views-table cols-3\">\n<thead>\n<tr>\n<th class=\"views-field views-field-field-analyst-company\" scope=\"col\">Company<\/th>\n<th class=\"views-field views-field-title\" scope=\"col\">Analyst<\/th>\n<th class=\"views-field views-field-field-analyst-phone\" scope=\"col\">Telephone<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr class=\"odd views-row-first\">\n<td class=\"views-field views-field-field-analyst-company\">Edison<\/td>\n<td class=\"views-field views-field-title\">Soo Romanoff &amp; Harry Shrives<\/td>\n<td class=\"views-field views-field-field-analyst-phone\"><a href=\"tel:+44 (0) 20 3077 5700\">+44 (0) 20 3077 5700<\/a><\/td>\n<\/tr>\n<tr class=\"even\">\n<td class=\"views-field views-field-field-analyst-company\">H.C. Wainwright &amp; Co<\/td>\n<td class=\"views-field views-field-title\">Joseph Pantginis<\/td>\n<td class=\"views-field views-field-field-analyst-phone\"><a href=\"tel:+1 646 975 6968\"> +1 646 975 6968<\/a><\/td>\n<\/tr>\n<tr class=\"odd\">\n<td class=\"views-field views-field-field-analyst-company\">Investec<\/td>\n<td class=\"views-field views-field-title\">Jens Lindqvist<\/td>\n<td class=\"views-field views-field-field-analyst-phone\"><a href=\"tel:+44 (0) 20 7597 5590\">+44 (0) 20 7597 5590<\/a><\/td>\n<\/tr>\n<tr class=\"even\">\n<td class=\"views-field views-field-field-analyst-company\">Liberum<\/td>\n<td class=\"views-field views-field-title\">Edward Thomason<\/td>\n<td class=\"views-field views-field-field-analyst-phone\"><a href=\"tel:+44 (0) 20 3205 7500\"> +44 (0) 20 3205 7500<\/a><\/td>\n<\/tr>\n<tr class=\"odd\">\n<td class=\"views-field views-field-field-analyst-company\">Numis<\/td>\n<td class=\"views-field views-field-title\">Paul Cuddon<\/td>\n<td class=\"views-field views-field-field-analyst-phone\"><a href=\"tel:+44 (0) 7260 1299\">+44 (0) 7260 1299<\/a><\/td>\n<\/tr>\n<tr class=\"even\">\n<td class=\"views-field views-field-field-analyst-company\">Panmure Gordon<\/td>\n<td class=\"views-field views-field-title\">Julie Simmonds<\/td>\n<td class=\"views-field views-field-field-analyst-phone\"><a href=\"tel:+44 (0) 20 7886 2743\">+44 (0) 20 7886 2743<\/a><\/td>\n<\/tr>\n<tr class=\"odd\">\n<td class=\"views-field views-field-field-analyst-company\">Peel Hunt<\/td>\n<td class=\"views-field views-field-title\">Miles Dixon<\/td>\n<td class=\"views-field views-field-field-analyst-phone\"><a href=\"tel:+44 (0) 20 3597 8663\">+44 (0) 20 3597 8663<\/a><\/td>\n<\/tr>\n<tr class=\"even\">\n<td class=\"views-field views-field-field-analyst-company\">RBC<\/td>\n<td class=\"views-field views-field-title\">Charles Weston<\/td>\n<td class=\"views-field views-field-field-analyst-phone\"><a href=\"tel:+44 (0) 20 7429 8425\"> +44 (0) 20 7429 8425<\/a><\/td>\n<\/tr>\n<tr class=\"odd views-row-last\">\n<td class=\"views-field views-field-field-analyst-company\">Stifel<\/td>\n<td class=\"views-field views-field-title\">James Orsborne &amp; Max Herrmann<\/td>\n<td class=\"views-field views-field-field-analyst-phone\"><a href=\"tel:+44 (0) 20 7710 7638\">+44 (0) 20 7710 7638<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 id=\"registrars\" class=\"h1\">Registrars<\/h2>\n<p class=\"text-blue\">All administrative enquiries relating to shareholdings and requests to receive corporate documents by email should, in the first instance, be directed to Link Registrars.<\/p>\n<p><strong>Link Group<\/strong><br \/>\n10th Floor<br \/>\nCentral Square<br \/>\n29 Wellington Street<br \/>\nLeeds LS1 4DL<br \/>\nEmail: <a href=\"mailto:shareholder.services@linkgroup.co.uk\">shareholder.services@linkgroup.co.uk<\/a><br \/>\nWebsite: <a href=\"https:\/\/www.signalshares.com\">www.signalshares.com<\/a><\/p>\n<h3>Enquiries<\/h3>\n<p>All administrative enquiries relating to shareholdings and requests to receive corporate documents by email should, in the first instance, be directed to Link Group, 10th Floor, Central Square, 29 Wellington Street, Leeds LS1 4DL. Telephone\u00a00371 664 0300 (calls cost 12p per minute plus network extras, lines are open 9.00am-5.30pm Mon-Fri) from the UK and\u00a0+44 371 664 0300 from outside the UK. Alternatively you could email them at: <a href=\"mailto:shareholder.services@linkgroup.co.uk\">shareholder.services@linkgroup.co.uk<\/a><\/p>\n<p>Shareholders who receive duplicate sets of company mailings because they have multiple accounts should write to the registrar to have the accounts amalgamated.<\/p>\n<p>By logging on to\u00a0<a href=\"https:\/\/www.signalshares.com\">www.signalshares.com<\/a> you can benefit from a number of online services as follows:<\/p>\n<ul>\n<li>View share price and current value of shareholding<\/li>\n<li>View shareholding details<\/li>\n<li>View share transaction history<\/li>\n<li>View details of dividends paid<\/li>\n<li>Apply\/change dividend mandate instruction<\/li>\n<li>Apply\/change dividend reinvestment plan mandate<\/li>\n<li>Change registered postal address<\/li>\n<li>Proxy voting<\/li>\n<li>Register an email address to receive future shareholder communications and reports via the Internet rather than by post<\/li>\n<\/ul>\n<p>You will need your investor code (IVC) which can be found on your share certificate(s) to register to use the Shareholder Portal.<\/p>\n<h3>Share dealing services<\/h3>\n<p>The Company has established the following share dealing services:<\/p>\n<p>Link Deal \u2013 a telephone and online share dealing service for UK shareholders. To use this service shareholders should contact Link Share Dealing Services on telephone: UK &#8211; 0371 664 0445 or visit <a href=\"https:\/\/www.linksharedeal.com\">www.linksharedeal.com<\/a>.<\/p>\n<h2>Investor contacts<\/h2>\n<p>Email the Investor Relations team at: <a href=\"mailto:ir@oxb.com\">ir@oxb.com<\/a><\/p>\n<div class=\"grid grid-layout-cols-1 md-grid-layout-cols-2 lg-grid-layout-cols-3 grid-gap-md\">\n<div>\n<h4>Company Secretary and Registered Office<\/h4>\n<p><strong>Natalie Walter<\/strong><br \/>\nOxford Biomedica plc<br \/>\nWindrush Court<br \/>\nTransport Way<br \/>\nOxford<br \/>\nOX4 6LT<br \/>\nUnited Kingdom<br \/>\nTel: +44 (0) 1865 783 000<\/p>\n<\/div>\n<div>\n<h4>Investor Relations<\/h4>\n<p><strong>Taylor Boyd<\/strong><br \/>\n1 Patriots Park<br \/>\nBedford<br \/>\nMA 01730<br \/>\nUnited States<br \/>\nTel: +1 919 539 1234<\/p>\n<p><strong>Sophia Bolhassan<\/strong><br \/>\nBuilding 9400<br \/>\nAlec Issigonnis Way<br \/>\nOxford Business Park<br \/>\nOxford OX4 2HN<br \/>\nUnited Kingdom<br \/>\nTel: +44 (0) 1865 509 737<\/p>\n<\/div>\n<div>\n<h4>Financial and Corporate Communications<\/h4>\n<p><strong>Consilium Strategic Communications<\/strong><br \/>\n85 Gresham Street<br \/>\nLondon<br \/>\nEC2V 7NQ<br \/>\nTel: +44 (0)20 3709 5700<br \/>\n<a href=\"https:\/\/www.consilium-comms.com\">www.consilium-comms.com<\/a><br \/>\n<a href=\"mailto:oxfordbiomedica@consilium-comms.com\">oxfordbiomedica@consilium-comms.com<\/a><\/p>\n<h4>Corporate Brokers<\/h4>\n<p><strong>Peel Hunt LLP (Corporate Brokers):<\/strong><br \/>\nJames Steel<br \/>\nChristopher Golden<br \/>\nTel: +44 (0)20 7418 8900<\/p>\n<p><strong>J P Morgan\u00a0(Joint Corporate Brokers):<\/strong><br \/>\nJames Mitford<br \/>\nGautham Baliga<br \/>\nTel: +44\u00a0207 1347329<\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Financial calendar Upcoming events Date 2022 Interim Results Announcement Q3 2022 Analyst coverage The following analysts<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-templates\/template-flex.php","meta":{"om_disable_all_campaigns":false,"footnotes":""},"class_list":["post-93","page","type-page","status-publish","hentry"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/oxb.com\/wp-json\/wp\/v2\/pages\/93","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oxb.com\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/oxb.com\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/oxb.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/oxb.com\/wp-json\/wp\/v2\/comments?post=93"}],"version-history":[{"count":0,"href":"https:\/\/oxb.com\/wp-json\/wp\/v2\/pages\/93\/revisions"}],"wp:attachment":[{"href":"https:\/\/oxb.com\/wp-json\/wp\/v2\/media?parent=93"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}